Balyasny Asset Management
MACK

Balyasny Asset Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Balyasny Asset Management’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-36,486
Closed -$123K – 1575
2016
Q3 		$123K Buy
+36,486
New +$1.51M ﹤0.01% 912
2015
Q3 		– Sell
-18,175
Closed -$1.77M – 1531
2015
Q2 		$1.77M Buy
+18,175
New +$1.73M 0.01% 753

Other funds holding MACK

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
WIM
Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Balyasny Asset Management's MACK Position: Q3 2018 in Review

Balyasny Asset Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2018, closing a stake of 32,105 shares — an estimated $124K sold.

Balyasny Asset Management first reported a position in MACK in Q4 2013 and held it in 12 quarters. The position peaked at $14.9M in Q2 2015. 63 funds tracked by Wall St. Rank hold MACK as of Q3 2018.

  • Balyasny Asset Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
  • Balyasny Asset Management sold 32,105 Merrimack Pharmaceuticals, Inc. shares in Q3 2018, an estimated $124K.
  • Balyasny Asset Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2013 and held it in 12 quarters.
  • Balyasny Asset Management's Merrimack Pharmaceuticals, Inc. position peaked at $14.9M in Q2 2015.
  • 63 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2018.

Based on Balyasny Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.